Nabid A, Garant MP, Martin AG, et al. Duration of androgen deprivation therapy in high risk prostate cancer: Final results of a randomized phase III trial. J Clin Oncol 35, 2017 (suppl; abstr 5008).
Afatinib gevolgd door osimertinib bij EGFR-gemuteerd NSCLC
okt 2018 | Longoncologie